Shield Therapeutics plc (AIM:STX)

Market Cap	112.14M +431.1%
Revenue (ttm)	30.29M +93.2%
Net Income	-15.50M
EPS	-0.02
Shares Out	1.07B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	216,854
Average Volume	2,035,620
Open	10.13
Previous Close	10.50
Day's Range	10.40 - 10.40
52-Week Range	2.10 - 12.50
Beta	1.96
RSI	49.62
Earnings Date	Sep 5, 2025

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 63
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: STX

Financial Performance

In 2024, Shield Therapeutics's revenue was $32.18 million, an increase of 145.93% compared to the previous year's $13.09 million. Losses were -$27.18 million, -18.36% less than in 2023.

Financial numbers in USD